Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: Bioconjug Chem. 2012 Jul 31;23(8):1513–1523. doi: 10.1021/bc200606s

Figure 1.

Figure 1

AuNP vaccine design (center). (A) MUC4 glycopeptides conjugated to the carbonyl highlighted in yellow of the linker shown in (C). R2-R4 indicate residues that are glycosylated. (B) C3d 28 residue peptide (P28) conjugated to the linker. The linker in (C) is shown modified with the addition of terminal hydroxyl group to maintain bioavailability and reduce density. The ratio of each thiol used in the construction of AuNPs was A:B:C = 1:1:3